In fulminant type 1 diabetic patients who survived and the pancreas was examined histologically by biopsy within 5 months postonset, there was no insulitis, but T-cell infiltration was observed in exocrine tissue. Because 60-70 % of fulminant type 1 diabetic patients have a history of flu-like symptoms before the onset of diabetes, a certain viral infection was suspected as the etiological mechanism. In fact, immunoglobulin A (IgA) antibody titer of enterovirus is elevated in fulminant type 1 diabetes [2] , and reactivation of human herpesvirus 6 (HHV-6) may cause fulminant type 1 diabetes in drug-induced hypersensitivity syndrome [3] . Moreover, encephalomyocarditis (EMC) virus induced a fulminant type 1 diabetes-like phenotype in a certain mouse strain [4] . These reports suggest the concept that fulminant type 1 diabetes may be caused by viral infection. However, it has been reported that CD8-dominant T-cell insulitis was clearly observed in a fulminant type 1 diabetic patient who died right after the onset of diabetes [5] , suggesting it may be caused by an autoimmune mechanism. Moreover, later studies indicated that islet-associated autoantibody may appear several months after disease onset [6] , and T-cell reactivity to isletassociated antigen is also detected [7] . Moreover, recent data indicate that islet-associated antibodies are detected in 18 % of patients with fulminant type 1 diabetes [8] , again suggesting it may be caused by autoimmunity. In a rodent model, a fulminant type 1 diabetes-like phenotype was observed in poly(I:C), mimic of double-stranded RNA (dsRNA)-injected CD28 knockout nonobese diabetic (NOD) mice, indicating that a fulminant type 1 diabeteslike phenotype can be induced in a mouse model of autoimmune diabetes [9] . CD28 knockout NOD mice possess a very low number of regulatory T cells compared with conventional NOD mice, and poly(I:C) injection is used to mimic RNA virus infection. In this model, not only beta cells but also alpha cells were reduced, and T-cell infiltration of exocrine tissue was observed, as in human fulminant type 1 diabetes. Therefore, viral infection may trigger the disease in regulatory T-cell-deficient autoimmune diabetes. In this situation, very recent reports have shown that anti-PD-1 antibody treatment for malignancies such as melanoma resulted in fulminant type 1 diabetes [10] . T cells are deactivated through inhibitory signals such as PD-1 and the ligand PD-L1 [11] . PD-1 inhibition by anti-PD-1 antibody is likely to trigger an autoimmune phenomenon. Therefore, these reports also strongly support the autoimmunity hypothesis. Moreover, importantly, these cases are reported in the Caucasian population, in which the disease is reported to be very rare [12] ; thus far, it is mainly reported in Japanese but also in the other Asian populations, such as Koreans [13] , Chinese [14] , and Filipinos [15] . However, case reports of anti-PD-1 antibody-triggered fulminant type 1 diabetes indicate that it is also seen in the Caucasian population and thus may be a global disease. The etiology of fulminant type 1 diabetes should be discussed worldwide in order to overcome this fatal subtype of type 1 diabetes.
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